Putin backs off for now...

Putin backs off for now... The S&P 500 hits an all-time high... Dan Ferris on Berkshire Hathaway... Klarman is worried about the markets... Big wins on NovaGold and Lorillard... Uranium hits a new high... Jeff Clark is bullish on gold...

 

 Global markets surged today as tensions eased between Ukraine and Russia.
 
There's no shortage of headlines on the topic, so we won't spend much time talking about it...
 
In short, Russia is backing down for now. Russian troops on the Ukrainian border were ordered to return to base. Russian President Vladimir Putin told the press, "As for the use of military force, there is no need for it... But we have that option." He also reiterated his support for "the legitimate [Ukrainian] President" Viktor Yanukovych, who was forced out of office.
 
 We doubt this conflict is close to over... But Mr. Market is happy today... The S&P 500 hit a record high.
 
 Yesterday, we noted investment legend Warren Buffett was buying stocks on market weakness. (He ignores macro factors, choosing to focus solely on business fundamentals.) Buffett stole headlines yesterday after his holding company, Berkshire Hathaway, announced record earnings. You can read yesterday's discussion of Buffett and Berkshire here.
 
 We asked Dan Ferris, who holds Berkshire Hathaway shares in his Extreme Value portfolio, for his thoughts on the company's announcement...
 
It's incredible that this huge company is still able to grow at a double-digit rate, and expects to be able to do so for some time. That's extremely rare. It's only possible here because it can participate in any business it wants. Most companies simply run out of ways to spend money when they get too big. If they still have a wonderful business (like the World Dominators), they just pay out bigger dividends. That's why you've seen Wal-Mart, Microsoft, ExxonMobil, and others doing huge dividend increases – sometimes 20% or more – in the past few years.
 
Berkshire is a better bet for investors than all those dividend-payers. It has an advantage those companies will never have. It can get into any business it wants. It can go around the world, buying businesses like holding company Marmon and manufacturer Iscar. It can buy big utility companies, like NV Energy, which supplies electricity for about 88% of Nevada's population. I remember a few years ago at the annual meeting, Buffett said he'd be able to invest $100 billion into the company's utility operation over the next 10 years. That's just one part of this huge company.
 
In other words, Berkshire can justify retaining and reinvesting 100% of its earnings. Very few companies can say that, but it's the absolute best way to compound shareholders' money. Berkshire is a huge company, with a market cap of almost $290 billion. Most companies that size can't be expected to grow much – let alone log the 18% increase in book value Berkshire turned in last year. Amazing.
 Another billionaire guru, Baupost Group founder Seth Klarman, just released his most recent shareholder letter. Baupost Group is one of the world's largest hedge funds, with around $25 billion under management. And in 2013, Klarman held a record high 50% of his fund in cash (up from 36% in 2012). He also announced he would return $4 billion to investors because he didn't want the fund to grow too quickly and dilute performance. (In other words, he doesn't see enough opportunity in the markets today.)
 
 Klarman has long been critical of the Federal Reserve's market manipulation. And while he acknowledges we're in the midst of a bull market, he's still skeptical. Value-investing website ValueWalk received a copy of Klarman's letter. From ValueWalk...
 
Seth Klarman noted that those "born bullish," those who "never met a stock market they didn't like" and those with "a consistently short memory," might look to the positives and ignore the negatives. "Price-earnings ratios, while elevated, are not in the stratosphere," he wrote, stating the bull case.
 
"Deficits are shrinking at the federal and state levels. The consumer balance sheet is on the mend. U.S. housing is recovering, and in some markets, prices have surpassed the prior peak. The nation is on the road to energy independence. With bonds yielding so little, equities appear to be the only game in town. The Fed will continue to hold interest rates extremely low, leaving investors no choice but to buy stocks. It doesn't matter that the S&P has almost tripled from its spring 2009 lows, or that the Fed has begun to taper purchases and interest rates have spiked.
 
Indeed, the stock rally on December's taper announcement is, for this contingent, confirmation of the strength of this bull market. The picture is unmistakably favorable. [Quantitative easing] has worked. If the economy or markets should backslide, the Fed undoubtedly stands ready to once again ride to the rescue. The Bernanke/Yellen put is intact. For now, there are no bubbles, either in sight or over the horizon."
 Klarman shares our views... We know how the Fed's market-boosting efforts will eventually end. But for now, the trend is up... We remain cautiously optimistic.
 
 Gold soared nearly 2.5% yesterday on fears surrounding the situation in Ukraine. (It's down today as fears subsided.) The precious metal hit a four-month high of $1,354 an ounce yesterday. Gold stocks, as measured by the Market Vectors Gold Miners Fund (GDX), were up 1.6%.
 
Stansberry's Investment Advisory recommendation NovaGold (NG) was up 1.9% yesterday. Porter and his research team recommended the gold miner in the November issue...
 
As we've explained, the best way to amplify our returns is to focus on those companies that are still in the pre-production life cycle. So the best call option on gold prices looks to be buying into the Donlin mine, via Barrick's partner NovaGold (NG).
 
We believe buying the Donlin mine is a fantastic way to amplify your returns as gold prices surge.
 
Donlin will be an open-pit mine. The project will look like a giant hole in the ground. This is part of the reason that Donlin has forecast an all-in production cost of only $735 an ounce. By comparison, the average all-in production cost for the industry is $1,235 an ounce.
 
Donlin's permitting process commenced in 2012 and is expected to take between three and four years. The project is situated on private land in southwest Alaska. Native Alaskans own the land. So far, they welcome the economic benefits that will come with Donlin's development. At this stage in the development process, Donlin requires between $30 million and $40 million of ongoing spending. This will continue until the permitting process concludes in 2016. Donlin's two owners – Barrick Gold and NovaGold – will split these annual costs.
 
NovaGold's market cap is around $700 million. At the end of the third quarter, NovaGold had $225 million in current assets and only around $20 million in debt. It also has a promissory note with Barrick for approximately $75 million. So the company has more than enough cash on hand to complete the permitting process.
 Stansberry's Investment Advisory subscribers are up 77% in less than four months.
 
 Another Porter recommendation, tobacco company Lorillard (LO), jumped more than 9% yesterday on rumors from the Financial Times that competitor Reynolds American may make a bid for the company. Reynolds has hired investment bank Lazar to explore the deal, which would value Lorillard at more than $20 billion, according to the Financial Times.
 
Neither company commented on the news. Lorillard shares are up another 1.5% as of midday trading today. As of yesterday's close, Porter's Stansberry Alpha subscribers were up 61% on margin... in just five days.
 
 We're also in the middle of a bull market in uranium – the metal used for nuclear energy.
 
DailyWealth Trader editor Amber Lee Mason noted uranium hit a two-year high in yesterday's Growth Stock Wire...
 
Uranium is the fuel used in nuclear power stations. And like most commodities, it goes through huge cycles of boom... and bust.
 
From 2003 to 2007, uranium saw a huge boom. It ran from $10 per pound to $130 per pound. But a sagging global economy helped pop the bubble. Prices fell all the way back down to around $40 a pound in three years.
 
In 2010, uranium rallied... But then the tsunami hit Japan's Fukushima power plant in early 2011. Japan was one of the world's biggest consumers of nuclear power, but the country shut down more than half of its reactors. Several other countries also scaled back their nuclear programs.
 
Uranium prices collapsed to new lows...
 
When it comes to commodities, the saying is "the cure for low prices is low prices." Uranium spot prices are now so low that most uranium miners can't make money. Eventually, that will force producers to shut down. And lower supply will lead to higher prices. Most uranium producers aren't going to start making money until prices double.
 
Another catalyst for higher prices will be improving sentiment toward the sector. On Tuesday, Japan released a draft of its energy policy. It includes nuclear power in the mix... The country could soon restart some of its 48 idle nuclear reactors.
 
The news sent uranium to a new high...
 S&A Resource Report subscribers are sitting on big gains from uranium giant Cameco. Shares are up 36% since editor Matt Badiali recommended them in December 2012.
 
 S&A Short Report editor Jeff Clark just made a big prediction...
 
While shares of gold and silver stocks have popped higher over the last couple months, one gold stock has been left behind. And Jeff thinks shares are about to jump higher... He believes the trade he just recommended to subscribers could return 135% over the next three months as the stock recovers.
 
As Jeff explained this morning, despite its recent rally, he sees more upside for gold stocks...
 
I've argued for the past couple weeks that the technical setup in the gold sector is unfavorable for new purchases. Miners are up 15%-50% in two months. The big money wants to buy on pullbacks, not into an overbought sector.
 
But every time the Market Vectors Gold Miners Fund (GDX) drops even a few pennies, buyers step up almost immediately. That's preventing a more significant pullback from occurring.
 
Here's an updated chart of GDX...
 
 
The rally in the gold sector really kicked into gear in January when the nine-day exponential moving average (EMA) crossed over the 50-day moving average (DMA). For the past couple weeks, though, GDX has been consolidating at resistance around $26.50. That matches up with last October's highs.
 
Rather than declining toward the support of the 50-DMA, GDX is marking time and giving the 50-DMA time to rally toward the current price.
 
That's bullish action. It tells us that GDX may be ready to make a run up toward the $30-per-share target price – its August high – sooner rather than later.
 The company Jeff just recommended a trade on is lagging other miners because its production and margins are on the decline. But as gold prices move higher, this company's margins and profits will improve. And shares are so beaten down, any good news could send the stock soaring higher.
 
 
 New 52-week highs (as of 3/3/14): Brazil Resources (BRI.V), Cameco (CCJ), CF Industries (CF), Denison Mines (DNN), Energy Transfer Equity (ETE), GigaMedia (GIGM), Lorillard (LO), and Skyworks Solutions (SWKS).
 
 One subscriber is enjoying his profits on Lorillard. Is your portfolio performing well with stocks at record highs? Let us know at feedback@stansberryresearch.com.
 
 "Okay, I was just about to let Porter have it and jump on the 'what have you done for me lately' bandwagon and boom! RJ Reynolds is milling around a buy out of Lorillard! What, did the RJ Reynolds hierarcy read Porter and companies call on Lorillard also? Nice! Buy the way, Porter has had some great energy plays in the last year also.
 
"Now, about this Russia, Ukrainian thing. Sadly I'm old enough to have seen this time and time again. Now that Putin, an ex-KGB guy, come on; this was unexpected? He would like nothing more than to assemble the old USSR bear. Get real and move on, he's already in there and will be extremely difficult to remove. I'm just glad this is taking his attention and diverting it from other areas of the world. Guess I better get out the old Beatles, White Album and listen to 'Back in the USSR.' Sounds like a plan! Nice call Porter!" – Paid-up subscriber Steve
 
Regards,
 
Sean Goldsmith
Miami Beach, Florida
March 4, 2014
 

 

Five medical breakthroughs that will change your life...
 
In today's Digest Premium, we share part of biotech expert Dave Lashmet's presentation from last weekend's Stansberry Society event.
 
Dave discussed five medical breakthroughs that will help you beat heart disease, cancer, stroke, and other potentially lethal afflictions. And he shared a few companies that are set to benefit from these long-term trends...
 
To subscribe to Digest Premium and receive a free hardback copy of Jim Rogers' latest book, click here.

 

Five medical breakthroughs that will change your life...

 

 Stansberry's Investment Advisory research analyst David Lashmet gave one of the best presentations at our first-ever Stansberry Society event in Miami. Dave is an expert in early-stage technologies (particularly in the biotechnology space).
 
His presentation was titled "65 is the New 45: Five Medical Breakthroughs by 2015." In it, he outlined five technologies that will help decrease heart attacks, increase cancer-survival rates, restore liver function, improve life for diabetics, and clear out Alzheimer's plaque.
 
 The No. 1 killer in the U.S. is heart disease (like heart attacks and strokes). Heart disease is tied to bad cholesterol. And right now, pharmaceutical companies are working on new ways to reduce its risks.
 
Several firms have developed drugs that are designed to cut cholesterols without taking statins (a specific type of cholesterol-reducing drug). Statins can reduce your cholesterols by 70%... The PCSK9, self-injectable drugs will reduce the risk of heart attack up to 75%... And the pivotal trials are this year. Dave expects we'll see these drugs on the market within two years.
 
 Three companies are producing these drugs: Amgen, Sanofi's Regeneron, and Pfizer. Dave says Amgen is in the lead... It reported results on 3,957 patients last month in final-phase clinical trials. And it's increasing that sample size. It's way ahead of its competitors in terms of testing.
 
Here is the slide from Dave's presentation:
 
 
– Sean Goldsmith
 
 
Editor's note: We're hosting our second Stansberry Society meeting in Dallas on May 31... It's focused on natural resources. And we've secured one of the world's biggest names in natural resources to speak at the conference: billionaire oilman T. Boone Pickens.
 
He's just one of the major speakers we've secured... We'll also have Sprott Resources investing legend Rick Rule and Texas wildcatter Cactus Schroeder, among others.
 
We're offering 200 "early bird" tickets to this event for only $299. We've already sold many of them. If you're interested, we'd urge you to act quickly. You can learn more here.

 

Five medical breakthroughs that will change your life...
 
In today's Digest Premium, we share part of biotech expert Dave Lashmet's presentation from last weekend's Stansberry Society event.
 
Dave discussed five medical breakthroughs that will help you beat heart disease, cancer, stroke, and other potentially lethal afflictions. And he shared a few companies that are set to benefit from these long-term trends...
 
To continue reading, scroll down or click here.

 

 

 

Stansberry & Associates Top 10 Open Recommendations
(Top 10 highest-returning open positions across all S&A portfolios)

 

 

As of 03/04/2014

 

 

Stock Symbol Buy Date Return Publication Editor
Prestige Brands PBH 05/13/09 369.8% Extreme Value Ferris
Constellation Brands STZ 06/02/11 282.1% Extreme Value Ferris
Enterprise EPD 10/15/08 266.8% The 12% Letter Dyson
Ultra Health Care RXL 03/17/11 245.8% True Wealth Sjuggerud
Ultra Nasdaq Biotech BIB 12/05/12 241.9% True Wealth Sys Sjuggerud
Fluidigm FLDM 08/04/11 215.2% Phase 1 Curzio
Ultra Health Care RXL 01/04/12 202.1% True Wealth Sys Sjuggerud
Fission Uranium FCU-V 04/30/13 189.6% Phase 1 Curzio
Hershey HSY 12/06/07 182.3% SIA Stansberry
Altria MO 11/19/08 170.7% The 12% Letter Dyson
Please note: Securities appearing in the Top 10 are not necessarily recommended buys at current prices. The list reflects the best-performing positions currently in the model portfolio of any S&A publication. The buy date reflects when the editor recommended the investment in the listed publication, and the return shows its performance since that date. To learn if a security is still a recommended buy today, you must be a subscriber to that publication and refer to the most recent portfolio.

 

 

 

Top 10 Totals
2 Extreme Value Ferris
2 The 12% Letter Dyson
1 True Wealth Sjuggerud
2 True Wealth Sys Sjuggerud
2 Phase 1 Curzio
1 SIA Stansberry

 

 

 

Stansberry & Associates Hall of Fame
(Top 10 all-time, highest-returning closed positions across all S&A portfolios)

 

 

Investment Sym Holding Period Gain Publication Editor
Seabridge Gold SA 4 years, 73 days 995% Sjug Conf. Sjuggerud
Rite Aid 8.5% bond   4 years, 356 days 773% True Income Williams
ATAC Resources ATC 313 days 597% Phase 1 Badiali
JDS Uniphase JDSU 1 year, 266 days 592% SIA Stansberry
Silver Wheaton SLW 1 year, 185 days 345% Resource Rpt Badiali
Jinshan Gold Mines JIN 290 days 339% Resource Rpt Badiali
Medis Tech MDTL 4 years, 110 days 333% Diligence Ferris
ID Biomedical IDBE 5 years, 38 days 331% Diligence Lashmet
Northern Dynasty NAK 1 year, 343 days 322% Resource Rpt Badiali
Texas Instr. TXN 270 days 301% SIA Stansberry

 

Back to Top